These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 32527506)
21. Advancing Precision Medicine for Alcohol Use Disorder: Replication and Extension of Reward Drinking as a Predictor of Naltrexone Response. Witkiewitz K; Roos CR; Mann K; Kranzler HR Alcohol Clin Exp Res; 2019 Nov; 43(11):2395-2405. PubMed ID: 31436886 [TBL] [Abstract][Full Text] [Related]
22. Effectiveness of naltrexone in a community treatment program. Killeen TK; Brady KT; Gold PB; Simpson KN; Faldowski RA; Tyson C; Anton RF Alcohol Clin Exp Res; 2004 Nov; 28(11):1710-7. PubMed ID: 15547458 [TBL] [Abstract][Full Text] [Related]
23. Naltrexone and disulfiram in patients with alcohol dependence and current depression. Petrakis I; Ralevski E; Nich C; Levinson C; Carroll K; Poling J; Rounsaville B; J Clin Psychopharmacol; 2007 Apr; 27(2):160-5. PubMed ID: 17414239 [TBL] [Abstract][Full Text] [Related]
24. Alcohol problems among patients attending five primary health care clinics in Harare city. Chinyadza E; Moyo IM; Katsumbe TM; Chisvo D; Mahari M; Cock DE; Mbengeranwa OL Cent Afr J Med; 1993 Feb; 39(2):26-32. PubMed ID: 8261500 [TBL] [Abstract][Full Text] [Related]
25. Acceptability of pharmacotherapy for hazardous alcohol use among men who have sex with men: Findings from a qualitative study. Hsiang E; Jennings D; Matheson T; Hern J; Euren J; Santos GM Addict Behav Rep; 2018 Dec; 8():122-127. PubMed ID: 30258972 [TBL] [Abstract][Full Text] [Related]
26. Alcoholism and pathways to recovery: new survey results on views and treatment options. To SE; Vega CP MedGenMed; 2006 Jan; 8(1):2. PubMed ID: 16915132 [TBL] [Abstract][Full Text] [Related]
27. Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety. O'Malley SS; Corbin WR; Leeman RF; DeMartini KS; Fucito LM; Ikomi J; Romano DM; Wu R; Toll BA; Sher KJ; Gueorguieva R; Kranzler HR J Clin Psychiatry; 2015 Feb; 76(2):e207-13. PubMed ID: 25742208 [TBL] [Abstract][Full Text] [Related]
28. Prevalence and characteristics of clients with co-occurring disorders in outpatient substance abuse treatment. Watkins KE; Hunter SB; Wenzel SL; Tu W; Paddock SM; Griffin A; Ebener P Am J Drug Alcohol Abuse; 2004 Nov; 30(4):749-64. PubMed ID: 15624547 [TBL] [Abstract][Full Text] [Related]
29. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. Anton RF; O'Malley SS; Ciraulo DA; Cisler RA; Couper D; Donovan DM; Gastfriend DR; Hosking JD; Johnson BA; LoCastro JS; Longabaugh R; Mason BJ; Mattson ME; Miller WR; Pettinati HM; Randall CL; Swift R; Weiss RD; Williams LD; Zweben A; JAMA; 2006 May; 295(17):2003-17. PubMed ID: 16670409 [TBL] [Abstract][Full Text] [Related]
30. Barriers to and Facilitators of Alcohol Use Disorder Pharmacotherapy in Primary Care: A Qualitative Study in Five VA Clinics. Williams EC; Achtmeyer CE; Young JP; Berger D; Curran G; Bradley KA; Richards J; Siegel MB; Ludman EJ; Lapham GT; Forehand M; Harris AHS J Gen Intern Med; 2018 Mar; 33(3):258-267. PubMed ID: 29086341 [TBL] [Abstract][Full Text] [Related]
31. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial. O'Malley SS; Sinha R; Grilo CM; Capone C; Farren CK; McKee SA; Rounsaville BJ; Wu R Alcohol Clin Exp Res; 2007 Apr; 31(4):625-34. PubMed ID: 17374042 [TBL] [Abstract][Full Text] [Related]
32. Low-threshold extended-release naltrexone for high utilizers of public services with severe alcohol use disorder: A pilot study. Smith-Bernardin S; Rowe C; Behar E; Geier M; Washington S; Santos GM; Euren J; Martin J; Gleghorn A; Coffin PO J Subst Abuse Treat; 2018 Feb; 85():109-115. PubMed ID: 29150316 [TBL] [Abstract][Full Text] [Related]
33. Right care, first time: a highly personalised and measurement-based care model to manage youth mental health. Hickie IB; Scott EM; Cross SP; Iorfino F; Davenport TA; Guastella AJ; Naismith SL; Carpenter JS; Rohleder C; Crouse JJ; Hermens DF; Koethe D; Markus Leweke F; Tickell AM; Sawrikar V; Scott J Med J Aust; 2019 Nov; 211 Suppl 9():S3-S46. PubMed ID: 31679171 [TBL] [Abstract][Full Text] [Related]
34. [Benefits in reducing alcohol consumption: how nalmefene can help]. Bendimerad P; Blecha L Encephale; 2014 Dec; 40(6):495-500. PubMed ID: 25454365 [TBL] [Abstract][Full Text] [Related]
35. [Out of addictions: Alcohol, or alcohol to alcohol]. Simmat-Durand L; Vellut N; Lejeune C; Jauffret-Roustide M; Mougel S; Michel L; Planche M Encephale; 2017 Aug; 43(4):326-333. PubMed ID: 27372354 [TBL] [Abstract][Full Text] [Related]
36. Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial. Oslin DW; Leong SH; Lynch KG; Berrettini W; O'Brien CP; Gordon AJ; Rukstalis M JAMA Psychiatry; 2015 May; 72(5):430-7. PubMed ID: 25760804 [TBL] [Abstract][Full Text] [Related]
37. Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels. Witkiewitz K; Hallgren KA; Kranzler HR; Mann KF; Hasin DS; Falk DE; Litten RZ; O'Malley SS; Anton RF Alcohol Clin Exp Res; 2017 Jan; 41(1):179-186. PubMed ID: 28019652 [TBL] [Abstract][Full Text] [Related]
38. Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial. Foa EB; Yusko DA; McLean CP; Suvak MK; Bux DA; Oslin D; O'Brien CP; Imms P; Riggs DS; Volpicelli J JAMA; 2013 Aug; 310(5):488-95. PubMed ID: 23925619 [TBL] [Abstract][Full Text] [Related]